Study of a new drug for giant cell tumor of bone
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental medication (JMT103) for people with giant cell tumor of bone that cannot be safely removed with surgery. The drug may help shrink the tumor or slow its growth, providing an option when surgery is too risky.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older, or at least 12 years old with fully grown bones and weigh at least 45 kg (about 99 lbs).
- Have a confirmed giant cell tumor of bone that cannot be removed with surgery, or surgery would cause serious disability.
- Be able to care for yourself (walking, daily activities) at a level of 0, 1, or 2 on a standard health scale.
- Have no active jaw or dental problems, and no planned dental surgery during the study.
- Have no other cancer (except certain skin or early cervical cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
This study looks at whether taking a bone-strengthening medicine called a bisphosphonate after surgery can lower the chance that a giant cell tumor in a leg or arm comes back. It may help prevent recurrence after removing the tumor from the bone.
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
This trial tests a new medicine (JMT103) against a standard treatment (zoledronic acid) to see if it is better at preventing bone complications like fractures, pain, or needing radiation or surgery on the bones. It is for people whose cancer has spread to their bones.
This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.
This trial compares a new drug called narlumosbart with denosumab (already used to treat bone problems) for people with multiple myeloma that has spread to the bone. The goal is to see if the new drug is as safe and effective at preventing bone complications.
Hear when a new Giant Cell Tumor of Bone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.